Journal articleLancet2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
- Journal
- Lancet
- Published
- 25 January 2017
- Citations
- 1,445
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 4
- BackgroundUsing Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620↗
- BackgroundMetronomic Chemotherapy With Capecitabine for Pancreatic Cancer NCT03959150↗
- BackgroundPancreatic Surgery in Elderly Patients NCT04893408↗
- BackgroundPancreatic and Periampullary Tumors in Greenland Inuit NCT05595811↗